Please login to the form below
tuberculosis
This page shows the latest tuberculosis news and features for those working in and with pharma, biotech and healthcare.
Evotec says Sanofi deal makes it anti-infectives powerhouse
regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.” It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria,
Latest news
-
Gates’ non-profit biotech for poverty diseases sets out its stall at BIO
Dedicated to the development of products to treat malaria, tuberculosis and diarrhoeal diseases and with a war chest from its parent of $273m over four years, Gates MRI has been in
-
Pharma must do more on antibiotic resistance, Davos meeting hears
for AMR and bring them to market responsibly,” citing the case of J&J’s new tuberculosis drug bedaquiline which is available in 100 countries with tight control of access.
-
J&J expands its TB research programme
Johnson and Johnson (J&J) has partnered with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to develop new treatments for tuberculosis (TB).
-
Just 20% of people living with hep C are aware of their status
The number of deaths attributed to viral hepatitis is comparable to those caused by tuberculosis and higher than those caused by HIV, but deaths from hepatitis are increasing while tuberculosis and
-
Dosing of GSK's malaria vaccine due to start in 2018
The Global Fund to Fight AIDS, Tuberculosis and Malaria has just approved $15m in funding for the malaria vaccine pilots, that according to the WHO assures full funding for the first
More from news
Approximately 16 fully matching, plus 106 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare (part 3)
and tuberculosis around the world.
-
The cultural construction of illness
and ‘consumptive’ appearance, driven by the perception of a link between tuberculosis and creativity.
-
Reactivating drug research programmes
One research-led breakthrough to hit the headlines involves the use of genome sequencing to isolate different strains of tuberculosis (TB), allowing the disease to be diagnosed more quickly.
-
Deal Watch February 2016
acquisition - company. 7, 200. Alere/Abbott Laboratories. portfolio of point of care diagnostics for infections such as HIV, tuberculosis, malaria, dengue.
-
Searching for health
We bring products to the market regularly.”. Success in HIV and multi-drug resistant tuberculosis are the highlights but Quiles is conscious of the need to translate innovation into market penetration.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Former Merck & Co exec to lead Seres
In total Dr Pomerantz has been involved with the development of eight approved drugs for infectious diseases, covering HIV, hepatitis C and tuberculosis.
-
GlycoVaxyn appoints Gerd Zettlmeissl as chairman
He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.
-
Former PEPFAR head Mark Dybul to lead the Global Fund
Joins at time of change for the AIDS, tuberculosis and malaria focused non-profit organisation. ... The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed renowned AIDS expert Dr Mark Dybul as executive director.
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
World AIDS Day 2018: Fighting the stigma surrounding HIV
2. Characterised by very low levels of CD4+ T cells, and the presence of AIDS-related pathologies (such as tuberculosis and Kaposi’s sarcoma), the diagnosis of AIDS marks just how
-
Could ketamine be the next big thing in depression?
Doctors noticed that tuberculosis patients treated with isoniazid showed signs of improved mood.
-
Exploring MINT: Part 4 - Turkey
due to migration to the urban centres of the west. In Eastern Turkey, outbreaks of communicable diseases such as tuberculosis are still occurring. Pharma investment therefore remains focused on the western
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Account Manager
-
Negotiable
-
Account Director
-
Competitive Salary Offered
-
Systematic Reviewer - Oxford
-
Negotiable
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Business Development Director – Health Education
-
excellent commission
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- Account Manager- Healthcare Advertising
-
Negotiable
-
Account Manager / Account Director
-
Competative
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
- Principal Health Economist - North-West
-
Negotiable
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical (Scientific) Director
-
£120, 000 benefits
-
Experienced Medical Writers
-
Competitive Salary and Benefits
Subscribe to our email news alerts
- Better together when buying medicines? Taking stock of the BeNeLuxA initiative
- Report: Achieving launch excellence in the challenging healthcare markets of today
- What is blockchain and why should i care - Richard Springham
- NHS medicines optimisation milestone
- AZ and CRUK launch Cambridge genomics centre
- eConsent: Busting regulatory myths
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
